Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Scott J. Antonia, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yokoi, Alberto Chiappori, Ki H. Lee, Maike de Wit, Byoung C. Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young-Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula OstorosKaoru Kubota, Jhanelle E. Gray, Luis Paz-Ares, Javier de Castro Carpeno, Catherine Wadsworth, Giovanni Melillo, Haiyi Jiang, Yifang Huang, Phillip Dennis, Mustafa Ozguroglu

Research output: Contribution to journalArticlepeer-review

3074 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science